-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
DICE Therapeutics (DICE) & Its Competitors Financial Review
DICE Therapeutics (DICE) & Its Competitors Financial Review
DICE Therapeutics (NASDAQ:DICE – Get Rating) is one of 950 public companies in the "Pharmaceutical preparations" industry, but how does it contrast to its peers? We will compare DICE Therapeutics to similar businesses based on the strength of its risk, institutional ownership, earnings, analyst recommendations, valuation, profitability and dividends.
Analyst Recommendations
This is a summary of recent recommendations and price targets for DICE Therapeutics and its peers, as provided by MarketBeat.
Get DICE Therapeutics alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
DICE Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
DICE Therapeutics Competitors | 3078 | 13011 | 39178 | 631 | 2.67 |
DICE Therapeutics currently has a consensus price target of $43.33, suggesting a potential upside of 116.88%. As a group, "Pharmaceutical preparations" companies have a potential upside of 95.82%. Given DICE Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe DICE Therapeutics is more favorable than its peers.
Valuation and Earnings
This table compares DICE Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.Gross Revenue | Net Income | Price/Earnings Ratio | |
DICE Therapeutics | $1.13 million | -$48.96 million | -5.23 |
DICE Therapeutics Competitors | $1.84 billion | $246.10 million | -4.06 |
DICE Therapeutics' peers have higher revenue and earnings than DICE Therapeutics. DICE Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares DICE Therapeutics and its peers' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
DICE Therapeutics | N/A | -24.27% | -22.74% |
DICE Therapeutics Competitors | -3,217.78% | -161.38% | -24.46% |
Institutional & Insider Ownership
95.4% of DICE Therapeutics shares are owned by institutional investors. Comparatively, 42.3% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 4.3% of DICE Therapeutics shares are owned by insiders. Comparatively, 15.0% of shares of all "Pharmaceutical preparations" companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
DICE Therapeutics beats its peers on 7 of the 12 factors compared.
DICE Therapeutics Company Profile
(Get Rating)
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
DICE Therapeutics (NASDAQ:DICE – Get Rating) is one of 950 public companies in the "Pharmaceutical preparations" industry, but how does it contrast to its peers? We will compare DICE Therapeutics to similar businesses based on the strength of its risk, institutional ownership, earnings, analyst recommendations, valuation, profitability and dividends.
骰子治療(納斯達克:骰子獲得評級)是950家上市公司中的一員,但它與同行有何不同?我們將根據其風險、機構所有權、收益、分析師建議、估值、盈利和股息的實力,將骰子治療公司與類似業務進行比較。
Analyst Recommendations
分析師建議
This is a summary of recent recommendations and price targets for DICE Therapeutics and its peers, as provided by MarketBeat.
這是由MarketBeat提供的對DICE治療公司及其同行的最近建議和價格目標的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
DICE Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
DICE Therapeutics Competitors | 3078 | 13011 | 39178 | 631 | 2.67 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
骰子治療學 | 0 | 0 | 6 | 0 | 3.00 |
Dice Treeutics的競爭對手 | 3078 | 13011 | 39178 | 631 | 2.67 |
DICE Therapeutics currently has a consensus price target of $43.33, suggesting a potential upside of 116.88%. As a group, "Pharmaceutical preparations" companies have a potential upside of 95.82%. Given DICE Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe DICE Therapeutics is more favorable than its peers.
骰子治療公司目前的共識目標價為43.33美元,暗示潛在上漲116.88%。作為一個整體,“醫藥製劑”公司有95.82%的潛在上行空間。鑑於DICE治療公司更高的共識評級和更高的可能上行空間,分析師們顯然認為DICE治療公司比其同行更有利。
Valuation and Earnings
估值和收益
Gross Revenue | Net Income | Price/Earnings Ratio | |
DICE Therapeutics | $1.13 million | -$48.96 million | -5.23 |
DICE Therapeutics Competitors | $1.84 billion | $246.10 million | -4.06 |
總收入 | 淨收入 | 市盈率 | |
骰子治療學 | 113萬美元 | -4,896萬元 | -5.23 |
Dice Treeutics的競爭對手 | 18.4億美元 | 2.461億美元 | -4.06 |
DICE Therapeutics' peers have higher revenue and earnings than DICE Therapeutics. DICE Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Dice治療公司的同行比Dice治療公司有更高的收入和收益。Dice治療公司的市盈率低於同行,這表明它目前比行業內的其他公司更負擔得起。
Profitability
盈利能力
This table compares DICE Therapeutics and its peers' net margins, return on equity and return on assets.
下表比較了Dice Treeutics及其同行的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
DICE Therapeutics | N/A | -24.27% | -22.74% |
DICE Therapeutics Competitors | -3,217.78% | -161.38% | -24.46% |
淨利潤率 | 股本回報率 | 資產回報率 | |
骰子治療學 | 不適用 | -24.27% | -22.74% |
Dice Treeutics的競爭對手 | -3,217.78% | -161.38% | -24.46% |
Institutional & Insider Ownership
機構與內部人持股
95.4% of DICE Therapeutics shares are owned by institutional investors. Comparatively, 42.3% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 4.3% of DICE Therapeutics shares are owned by insiders. Comparatively, 15.0% of shares of all "Pharmaceutical preparations" companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
DICE治療公司95.4%的股份由機構投資者持有。相比之下,所有“醫藥製劑”公司42.3%的股份由機構投資者持有。Dice Treateutics 4.3%的股份由內部人士持有。相比之下,所有“醫藥製劑”公司15.0%的股份為內部人所有。強大的機構持股表明,大型基金管理公司、捐贈基金和對衝基金相信,一家公司的長期表現將好於大盤。
Summary
摘要
DICE Therapeutics beats its peers on 7 of the 12 factors compared.
Dice Treateutics在比較的12個因素中有7個超過了同行。
DICE Therapeutics Company Profile
戴斯治療公司簡介
(Get Rating)
(獲取評級)
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Dice Treateutics,Inc.是一家生物製藥公司,該公司製造了各種口服治療候選藥物,用於治療免疫學和其他治療領域的慢性病。其平臺DELSCAPE旨在發現選擇性口服小分子,以與系統生物學一樣有效地調節蛋白質-蛋白質相互作用(PPI)。該公司的主要候選治療藥物是DC-806,一種促炎信號分子IL-17的口服拮抗劑,它是一種與各種免疫學適應症有關的有效藥物靶點。該公司還在開發針對A4?7整合素的口服治療候選藥物,用於治療炎症性腸道疾病,以及針對AV?1/AV?6整合素,用於治療特發性肺纖維化。此外,該公司還專注於抗體療法的免疫腫瘤學。該公司成立於2013年,總部位於加利福尼亞州舊金山南部。
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受DICE治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Dice Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧